Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
7.24
-0.01 (-0.09%)
Feb 21, 2025, 4:00 PM EST - Market closed
Daxor Revenue
Daxor had revenue of $71.76K in the half year ending June 30, 2024, a decrease of -46.94%. This brings the company's revenue in the last twelve months to $154.21K, down -13.06% year-over-year. In the year 2023, Daxor had annual revenue of $163.42K, down -29.45%.
Revenue (ttm)
$154.21K
Revenue Growth
-13.06%
P/S Ratio
227.34
Revenue / Employee
$4,168
Employees
37
Market Cap
35.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
Dec 31, 2019 | 380.14K | -49.82K | -11.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DXR News
- 4 days ago - Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 - GlobeNewsWire
- 5 days ago - TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team - Business Wire
- 5 days ago - Daxor to Exhibit at World's Largest Critical Care Conference - GlobeNewsWire
- 9 days ago - Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment - GlobeNewsWire
- 10 days ago - New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care - GlobeNewsWire
- 2 months ago - Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum - GlobeNewsWire
- 4 months ago - DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 - GlobeNewsWire
- 4 months ago - Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire